---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-018807"
form_type: "8-K"
ticker: "ORIC"
cik: "0001796280"
company_name: "Oric Pharmaceuticals, Inc."
filed_at: "2023-05-08T23:59:59+00:00"
generated_at: "2026-06-15T13:59:01.599110+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# ORIC reports Q1 cash $208.9M; three Phase 1b data readouts expected H2 2023

## Summary
- Cash and investments $208.9M as of March 31, 2023; funds operations into H1 2025.
- R&D expenses $19.5M (up $2.7M YoY) driven by clinical and discovery program advancement.
- G&A expenses $6.2M, down $0.3M YoY.
- Initial Phase 1b data expected H2 2023 for ORIC-533 (myeloma), ORIC-114 (EGFR/HER2), and ORIC-944 (prostate).
- Preclinical data for ORIC-944 biomarker strategy and PLK4 program presented at AACR 2023.

## SEC filing metadata
- accession: 0000950170-23-018807
- form_type: 8-K
- ticker: ORIC
- cik: 0001796280
- company_name: Oric Pharmaceuticals, Inc.
- filed_at: 2023-05-08T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1796280/000095017023018807/0000950170-23-018807-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1796280/000095017023018807/oric-20230508.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-018807
- JSON: https://secwatch.observer/filing/0000950170-23-018807.json
- Plain text: https://secwatch.observer/filing/0000950170-23-018807.txt

## Key facts
- Earnings Releases
  Oric Pharmaceuticals, Inc. reported financial results for the quarter ended March 31, 2023.
  - Period: the quarter ended March 31, 2023
  - Result: reported results
  source text: On May 8, 2023, ORIC Pharmaceuticals, Inc. issued a press release announcing its financial results for the fiscal quarter ended March 31, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1796280/000095017023018807/0000950170-23-018807-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.